Solid Current Deferred Revenue from 2010 to 2026

SLDB Stock  USD 6.18  0.10  1.64%   
Solid Biosciences' Current Deferred Revenue is increasing over the years with slightly volatile fluctuation. Current Deferred Revenue is expected to dwindle to about 6.7 M. Current Deferred Revenue is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. View All Fundamentals
 
Current Deferred Revenue  
First Reported
2010-12-31
Previous Quarter
9.3 M
Current Value
6.7 M
Quarterly Volatility
4.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Solid Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Solid Biosciences' main balance sheet or income statement drivers, such as Interest Income of 11.4 M, Depreciation And Amortization of 2.1 M or Interest Expense of 371.4 K, as well as many indicators such as Price To Sales Ratio of 10.66, Dividend Yield of 0.0 or PTB Ratio of 1.12. Solid financial statements analysis is a perfect complement when working with Solid Biosciences Valuation or Volatility modules.
  
Build AI portfolio with Solid Stock
Check out the analysis of Solid Biosciences Correlation against competitors.
Analyzing Solid Biosciences's Current Deferred Revenue over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Current Deferred Revenue has evolved provides context for assessing Solid Biosciences's current valuation and future prospects.

Latest Solid Biosciences' Current Deferred Revenue Growth Pattern

Below is the plot of the Current Deferred Revenue of Solid Biosciences LLC over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Solid Biosciences' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Solid Biosciences' overall financial position and show how it may be relating to other accounts over time.
Current Deferred Revenue10 Years Trend
Slightly volatile
   Current Deferred Revenue   
       Timeline  

Solid Current Deferred Revenue Regression Statistics

Arithmetic Mean4,630,049
Geometric Mean1,826,683
Coefficient Of Variation91.62
Mean Deviation4,046,164
Median6,678,834
Standard Deviation4,241,948
Sample Variance18T
Range10.1M
R-Value0.82
Mean Square Error6.2T
R-Squared0.67
Significance0.000053
Slope689,958
Total Sum of Squares287.9T

Solid Current Deferred Revenue History

20266.7 M
20259.3 M
20218.1 M
202010.4 M
20199.2 M
20188.2 M
2017233 K

About Solid Biosciences Financial Statements

Solid Biosciences stakeholders use historical fundamental indicators, such as Solid Biosciences' Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Solid Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Solid Biosciences' assets and liabilities are reflected in the revenues and expenses on Solid Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Solid Biosciences LLC. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue9.3 M6.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Solid Biosciences LLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Solid Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Solid Biosciences Llc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Solid Biosciences Llc Stock:
Check out the analysis of Solid Biosciences Correlation against competitors.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Solid Biosciences. If investors know Solid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Solid Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(2.48)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.44)
Return On Equity
(0.87)
Understanding Solid Biosciences LLC requires distinguishing between market price and book value, where the latter reflects Solid's accounting equity. The concept of intrinsic value - what Solid Biosciences' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Solid Biosciences' price substantially above or below its fundamental value.
Please note, there is a significant difference between Solid Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Solid Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Solid Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.